-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The pathogenesis of systemic lupus erythematosus (SLE) involves a variety of disorders of innate and adaptive immune pathways
Immune blood vessel
Existing studies have shown that the risk of cardiovascular disease (CVD) and premature arteriosclerosis is significantly increased in systemic lupus erythematosus, especially in young women
Cardiovascular
The immune disorders of systemic lupus erythematosus are believed to play a prominent role in promoting premature atherosclerosis
The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway is a basic signal cascade that is used by cells to respond to the effects of various cytokines and growth factors
Existing studies have shown that in animal models of lupus, Janus kinase (JAK) inhibitor tofacitinib can improve clinical disease characteristics, immune disorders and vascular dysfunction
Randomized, double-blind, placebo-controlled randomized, double-blind, placebo-controlled
In this study, 30 subjects were randomized to receive tofacitinib (5 mg, twice a day) or placebo in a 2:1 interval
Safety and tolerabilitySafety and tolerabilityClinical response and mechanism researchClinical response and mechanism research
Outcome Scale of Disease Activity and Patient Report
Disease Activity and Patient Reported Outcome Scales Disease Activity and Patient Reported Outcome ScalesThe results show that tofacitinib is safe in the treatment of systemic lupus erythematosus and meets the primary endpoint of the study
tofacitinib in the treatment of systemic lupus erythematosus in the process of security tofacitinib is safe in the treatment of systemic lupus erythematosus in the process of change good with systemic lupus erythematosus atherosclerosis-related cardiac metabolic and immunological parameters premature to change the good and the system lupus erythematosus premature atherosclerosis-related cardiac metabolic and immunological parameters of cholesterol in a subject STAT4 risk allele is more powerful in the risk allele of STAT4 have a more powerful subjects
Original source:
Original source:Sarfaraz A.
Sarfaraz A.
Leave a message here